Is nerve growth factor deficiency a marker for early detection of subclinical diabetic neuropathy?
Scientific Journal of Al-Azhar Medical Faculty [Girls] [The]. 2003; 24 (1): 625-43
Dans Anglais
| IMEMR
| ID: emr-64796
ABSTRACT
Nerve growth factor [NGF] and nerve conductive study [NCS] were evaluated in 80 diabetic patients [35 males and 45 females and their mean age was 44.2 +/- 7.2 years] and 15 healthy control subjects [6 males and 9 females, their mean age was 43.7 +/- 6.1 years and their neuropathy score was zero]. The patients were classified into three subgroups. Subgroup A [diabetic without neuropathy] included 20 patients. Subgroup B [diabetics with subclinical neuropathy] included 40 patients. Subgroup C [diabetic with neuropathy] included 20 patients. Also, patients were classified according to some variables [according to age into two subgroups, according to duration of diabetes into three subgroups and according to type of treatment into two subgroups]. It can be concluded that, nerve growth factor is deficient in diabetics, nerve growth factor is a sensitive and reliable marker for early detection of subclinical neuropathy in diabetics, and early insulin prescription to type II diabetics who are in need could be of neuroprotection value
Recherche sur Google
Indice:
Méditerranée orientale
Sujet Principal:
Peptide C
/
Test ELISA
/
Anticorps antinucléaires
/
Diabète
/
Tests de la fonction hépatique
/
Facteurs de croissance nerveuse
/
Conduction nerveuse
Type d'étude:
Étude de dépistage
Limites du sujet:
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Sci. J. Al-Azhar Med. Fac. [Girls]
Année:
2003
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS